Dosing of tissue plasminogen activator often differs from 0.9 mg/kg, but does not affect the outcome

Petr Aulicky, Alejandro Rabinstein, Raymond C.S. Seet, Jiri Neumann, Robert Mikulik

Research output: Contribution to journalArticlepeer-review

17 Scopus citations


Background: The safety and efficacy of low- and high-dose intravenous tissue plasminogen activator (t-PA) for the treatment of acute ischemic stroke are poorly understood. In this multicenter study, we examined the relationships between different doses of t-PA and outcome. Methods: Between 2006 and 2010, patients were enrolled if they were treated with t-PA on the basis of estimated body weight and on the subsequent availability of actual body weight. Based on the actual weight, patients were divided into lower (<0.85 mg/kg), standard (0.85-0.95 mg/kg), and higher (>0.95 mg/kg) t-PA dose groups. Differences in the outcomes of these groups were compared in terms of functional recovery (modified Rankin Scale [mRS] 0-1) at 3 months and the incidence of parenchymal hemorrhages on follow-up computed tomographic scans. Results: This cohort study included 272 patients: 171 (63%) patients received the standard t-PA dose, 62 (23%) a lower dose, and 39 (14%) a higher dose. At 3 months, 51% of the standard dose patients achieved a mRS score of 0 to 1, compared with 50% in the lower dose and 44% in the higher dose groups. Parenchymal hemorrhage occurred in 4.7%, 6.5%, and 7.7% of patients in standard, lower, and higher dose groups, respectively. Compared with standard dose groups, no significant differences in functional recovery and parenchymal hemorrhage were observed in the lower and higher dose groups. Conclusions: In clinical practice, the actual dose of t-PA often differs from the recommended dose of 0.9 mg/kg, but this has no significant impact on the outcome after t-PA treatment.

Original languageEnglish (US)
Pages (from-to)1293-1297
Number of pages5
JournalJournal of Stroke and Cerebrovascular Diseases
Issue number8
StatePublished - Nov 2013


  • Acute ischemic stroke
  • efficacy of treatment
  • safety of treatment
  • thrombolysis
  • tissue plasminogen activator dose

ASJC Scopus subject areas

  • Surgery
  • Rehabilitation
  • Clinical Neurology
  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Dosing of tissue plasminogen activator often differs from 0.9 mg/kg, but does not affect the outcome'. Together they form a unique fingerprint.

Cite this